TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07446439: A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use

Sponsor: Vanda Pharmaceuticals · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 280 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$2,687,208

Rescue Site Savings

+$1,791,472

Unlock Full NCT07446439 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07446439 Rescue Dossier →